MICHELLE STONE: Open Payments
NPI 1093257289 · SUMMIT, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,960 in 119 payments from 32 companies in 2025. Trend: 2023 $1,552 · 2024 $1,451 · 2025 $1,960
Food & beverage: $1,960
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 22 | $292 |
| Lilly USA, LLC | 17 | $276 |
| Vifor Pharma, Inc. | 9 | $140 |
| Travere Therapeutics, Inc. | 6 | $103 |
| Xeris Pharmaceuticals, Inc. | 6 | $97 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $85 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $78 |
| Calliditas Therapeutics US Inc. | 4 | $75 |
| Ardelyx, Inc. | 4 | $75 |
| Amgen Inc. | 5 | $74 |
Products named: JARDIANCE, Rybelsus, Veltassa, GVOKE HYPOPEN, Ozempic, MOUNJARO, Kerendia, TARPEYO.
Industry payments across NJ — which companies pay providers there.
